a1 Aging and Dementia Research Center, Silberstein Institute, New York University School of Medicine, New York, New York, U.S.A. Email: firstname.lastname@example.org
a2 McGill Center for Studies in Aging, Douglas Hospital, Montréal, Quebec, Canada
At the present time, there is increasing recognition and understanding of the mild cognitive impairment (MCI) entity as a stage which is a frequent precursor and harbinger of subsequently manifest Alzheimer's disease (AD) and, perhaps, other related conditions, such as vascular dementia (Gauthier et al., 2006). MCI has been defined in two disparate but generally compatible ways in the current literature (see Reisberg et al., 2008 (this issue), for a more complete historical overview of MCI). These two definitional approaches might be termed: (a) the clinical approach to MCI, and (b) the clinical plus psychometric approach to MCI.